Health · Pharma & Biotech · 3 hrs ago
FDA approves Roche breast cancer drug for patients with ESR1 mutation
The FDA approved Roche’s giredestrant for certain adults with advanced breast cancer.
The treatment is for cancer that is estrogen-receptor positive, HER2-negative and has an ESR1 mutation.
This mutation can signal that the cancer is becoming resistant to standard treatments.
The drug is taken by mouth and is used with everolimus after cancer returns or progresses during or after certain hormone treatments.
In the evERA trial, the combination significantly extended the time before cancer worsened among patients with the mutation.
The FDA also cleared a blood test to find ESR1 mutations and identify people who may receive the treatment.
The FDA approved Roche’s giredestrant, also known as Wilserdly, for certain patients with advanced breast cancer carrying an ESR1 mutation.
The treatment is used with everolimus for adults with estrogen receptor-positive, HER2-negative, locally advanced or metastatic disease.
The approval covers patients whose disease returned during or after adjuvant endocrine therapy, or progressed during at least one endocrine therapy for metastatic disease.
The FDA also approved FoundationOne Liquid CDx, a blood test to identify ESR1 mutations and help select patients for treatment.
In the phase III evERA trial, the combination significantly improved progression-free survival in patients with an ESR1 mutation.
- Who
- The FDA approved Roche’s giredestrant in combination with everolimus.
- What
- The approval covers certain adults with advanced breast cancer carrying an ESR1 mutation.
- When
- Monday, November 16, 2026.
- Where
- The United States.
- Why
- The treatment is for patients whose disease returned or progressed after endocrine therapy and whose cancer has an ESR1 mutation.
This story does not have two clearly opposing sides.
The phase III study enrolled 373 adults, including 207 with an ESR1 mutation, and found a statistically significant progression-free survival improvement for the combination in patients with the mutation.
The FDA approved giredestrant with everolimus and also approved FoundationOne Liquid CDx as a companion diagnostic.
- Drug
- Giredestrant, also known as Wilserdly
- Combination
- Everolimus
- Trial
- Phase III evERA; 373 adults, including 207 with an ESR1 mutation
- Companion diagnostic
- FoundationOne Liquid CDx, a blood test
- Review
- Project Orbis, with Health Canada and Israel’s health ministry